Participants will attend scheduled study visits to receive their vaccine and will record symptoms on a daily eDiary. conditions: HIV studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 50 type: ESTIMATED name: 16055 NFL delta Gly4 trimer name: Trimer 4571 name: Ad4-Env145NFL, 5 x 108 viral particles (vp) measure: Local reactogenicity signs and symptoms measure: Systemic reactogenicity signs and symptoms measure: Number of adverse events (AEs) reported for 30 days after receipt of any study product measure: Number of Serious Adverse Reactions (SAEs) leading to early participant withdrawal or permanent discontinuation measure: Number of Medically Attended Adverse Event (MAAEs) leading to early participant withdrawal or permanent discontinuation measure: Number of Adverse Events of Special Interest (AESIs) that are Potential Immune Mediated Medical Conditions (PIMMCs) leading to early participant withdrawal or permanent discontinuation measure: Number of Adverse Events (AEs) leading to early participant withdrawal or permanent discontinuation measure: Occurrence of serum IgG binding antibodies to vaccine-matched HIV-1 Env trimers and specific epitopes (e.g., CD4 binding site, V2, base of trimer, etc) measure: Magnitude of serum IgG binding antibodies to vaccine-matched HIV-1 Env trimers and specific epitopes (e.g., CD4 binding site, V2, base of trimer, etc.) measure: Response Rate of serum IgG binding antibodies to vaccine-matched HIV-1 Env trimers and specific epitopes (e.g., CD4 binding site, V2, base of trimer, etc.) measure: Occurrence of serum antibody neutralization of the autologous pseudovirus HIV-1 strains (including vaccine-matched deglycosylated 16055, WT 16055, BG505, 1086) measure: Magnitude of serum antibody neutralization of the autologous pseudovirus HIV-1 strains (including vaccine-matched deglycosylated 16055, WT 16055, BG505, 1086) measure: Response Rate of serum antibody neutralization of the autologous pseudovirus HIV-1 strains (including vaccine-matched deglycosylated 16055, WT 16055, BG505, 1086) measure: Occurrence of serum antibody neutralization of HIV-1 strains measure: Magnitude of serum antibody neutralization of HIV-1 strains measure: Response Rate of serum antibody neutralization of HIV-1 strains measure: Flow cytometry analysis of the frequency of Env-specific IgG+ B cells measure: Occurrence of serum IgG binding antibodies as measured by BAMA measure: Magnitude of serum IgG binding antibodies as measured by BAMA measure: Response Rate of serum IgG binding antibodies as measured by BAMA measure: Number of Isolation of CD4bs bnAb specific VH and VL alleles and characteristic mutations measure: Flow cytometry analysis of the frequency of Env-specific IgG+ B cells at 26 weeks and 52 weeks after the fifth vaccination measure: Occurrence of serum IgG binding antibodies measure: Magnitude of serum IgG binding antibodies measure: Response Rate of serum IgG binding antibodies measure: Occurrence of serum antibody neutralization to tier 2 HIV-1 strains measure: Magnitude of serum antibody neutralization to tier 2 HIV-1 strains measure: Response Rate of serum antibody neutralization to tier 2 HIV-1 strains measure: Epitope specific response rates as measured by electron microscopy polyclonal epitope mapping (EMPEM) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Alabama CRS status: NOT_YET_RECRUITING city: Birmingham state: Alabama zip: 35222 country: United States name: Heather Logan, ANP role: CONTACT phone: 205-873-8686 email: heatherlogan@uabmc.edu lat: 33.52066 lon: -86.80249 facility: The Ponce de Leon Center CRS status: NOT_YET_RECRUITING city: Atlanta state: Georgia zip: 30308 country: United States name: Erika Patrick, MSN role: CONTACT phone: 404-616-6313 email: erpatri@emory.edu lat: 33.749 lon: -84.38798 facility: Brigham and Women's Hospital Vaccine CRS (BWH VCRS) status: NOT_YET_RECRUITING city: Boston state: Massachusetts zip: 02115 country: United States name: Jose Licona, MD role: CONTACT phone: 617-525-9433 email: jlicona@partners.org lat: 42.35843 lon: -71.05977 facility: Columbia Partnership for Prevention and Control of HIV/AIDS CTU status: NOT_YET_RECRUITING city: New York state: New York zip: 10032 country: United States name: Mascha Elskamp role: CONTACT phone: 212-305-2201 email: Me2500@cumc.columbia.edu lat: 40.71427 lon: -74.00597 facility: University of Rochester HIV/AIDS CTU status: NOT_YET_RECRUITING city: Rochester state: New York zip: 14642 country: United States name: Catherine Bunce, RN MS, CCRC role: CONTACT phone: 585-275-5871 email: catherine_bunce@urmc.rochester.edu lat: 43.15478 lon: -77.61556 facility: University of Pennsylvania HIV Therapeutics and Prevention Clinical Trials Unit status: RECRUITING city: Philadelphia state: Pennsylvania zip: 19104 country: United States name: Debora Dunbar, MSN, CRNP role: CONTACT phone: 215-746-3713 email: ddunbar@pennmedicine.upenn.edu lat: 39.95233 lon: -75.16379 hasResults: False